Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thyroid Diseases × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 29 Carcinoma, Hepatocellular 20 Small Cell Lung Carcinoma 14 Sarcoma 12 Ovarian Neoplasms 12 Colorectal Neoplasms 12 Carcinoma, Non-Small-Cell Lung 12 Breast Neoplasms 10 Nasopharyngeal Carcinoma 9 Esophageal Squamous Cell Carcinoma 9 Cholangiocarcinoma 9 Triple Negative Breast Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 6 Lung Neoplasms 6 Pancreatic Neoplasms 5 Osteosarcoma 5 Head and Neck Neoplasms 5 Esophageal Neoplasms 5 Biliary Tract Neoplasms 5 Melanoma 4 Uterine Cervical Neoplasms 3 Thyroid Neoplasms 3 Solid Tumor 3 Recurrence 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Glioma 3 Carcinoma, Adenoid Cystic 3 Neoplasms 2 Nasopharyngeal Neoplasms 2

Interventions

Sorafenib 3 cabozantinib 2 vandetanib 1 temsirolimus 1 pembrolizumab 1 lenvatinib 1 apatinib 1 Vitamin B 12 1 Thyrotropin-Releasing Hormone 1 Pemetrexed 1 Panobinostat 1 Metformin 1 Folic Acid 1 Fluorescein 1 Everolimus 1 Cisplatin 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04180007 2019-11-27

APT-01

Nanjing First Hospital, Nanjing Medical University

Phase 2 Unknown

Neoplasm Metastasis, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡